Investigational drug · Phase 2
HL-085
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neurofibromatosis 1, Plexiform Neurofibromas.
Phase 2Last checked: Nov 19, 2026Latest source record: May 31, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
11
Any phase or sponsor naming "HL-085"
First trial start
2021
Oct 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HL-085", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neurofibromatosis 1
- Plexiform Neurofibromas
Largest trials
Live from ClinicalTrials.gov: studies naming "HL-085" as an intervention, largest first.
Shanghai Kechow Pharma, Inc.Industry
NCT05233332 · 186 participants (planned) · Start Feb 24, 2022 · Primary completion Jan 20, 2024
Drug: HL-085; Vemurafenib · For: CRC
Sites: Beijing, China
Shanghai Kechow Pharma, Inc.Industry
NCT05263453 · 104 participants (planned) · Start Sep 6, 2021 · Primary completion Sep 30, 2024
Drug: HL-085; Vemurafenib · For: Melanoma
Sites: Beijing, China
Shanghai Kechow Pharma, Inc.Industry
NCT05217303 · 100 participants · Start Nov 2, 2020 · Primary completion Feb 19, 2023
Drug: HL-085 · For: Melanoma
Sites: Beijing, China · 2 sites in all
Shanghai Kechow Pharma, Inc.Industry
NCT05900219 · 75 participants (planned) · Start Sep 24, 2023 · Primary completion Sep 24, 2025
Drug: HL-085+Vemurafenib · For: Non-small-cell Lung Cancer
- HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasRecruiting
Shanghai Kechow Pharma, Inc.Industry
NCT05331105 · 70 participants (planned) · Start Oct 18, 2021 · Primary completion Oct 30, 2025
Drug: HL-085 · For: Neurofibromatosis 1; Plexiform Neurofibromas
Sites: Shanghai, China
Shanghai Kechow Pharma, Inc.Industry
NCT03781219 · 45 participants (planned) · Start Jul 1, 2018 · Primary completion Dec 1, 2023
Drug: HL-085; Vemurafenib · For: Solid Tumor
Sites: Beijing, China; Zhengzhou, China; Hangzhou, China · 4 sites in all
Shanghai Kechow Pharma, Inc.Industry
NCT03973151 · 42 participants · Start Sep 1, 2017 · Primary completion Jan 18, 2021
Drug: HL-085 · For: Melanoma
Sites: Beijing, China; Shanghai, China
Kechow Pharma, Inc.Industry
NCT04683354 · 28 participants · Start Dec 23, 2020 · Primary completion Sep 15, 2022
Drug: HL-085 · For: Solid Tumor, Adult
Sites: San Marcos, California; Las Vegas, Nevada; Canton, Ohio · 5 sites in all
- Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid TumorsRecruiting
Tianjin Medical University Second HospitalAcademic, hospital or other
NCT07170293 · 15 participants (planned) · Start Aug 31, 2027 · Primary completion Sep 30, 2027
Drug: Tunlametinib · For: Solid Cancers
Sites: Tianjin, China
Shanghai Kechow Pharma, Inc.Industry
NCT03976050 · 4 participants · Start Jun 17, 2019 · Primary completion Nov 12, 2020
Drug: HL-085 · For: Solid Tumor, Adult
Sites: Austin, Texas; San Antonio, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Tunlametinib Suppresses Melanogenesis Induces Cell Cycle Arrest and Apoptosis in Giant Congenital Melanocytic Nevus Cells.
Guan JY, Chen Z, Liu WS, et al. · Cancers (Basel) 2026
- Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study.
Shi Y, Han X, Zhao Q, et al. · Exp Hematol Oncol 2024
- First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations.
Wang X, Luo Z, Chen J, et al. · BMC Med 2023
- Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma.
Zhao Q, Wang T, Wang H, et al. · Front Pharmacol 2022
Also in development for Neurofibromatosis 1
- luvometinibFCN-159Phase 34 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Non-small Cell Lung Caner, KRAS-mutated, Metastasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.